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Autosomal dominant medullary cystic kidney disease type 2
(MCKD2) is a tubulo-in terstitial nephropathy that causes renal
salt wasting, hyperuricemia, gout, and end-stage renal failure in
the fifth decade of life. This disorder was described to have an
age of onset between the age of 20–30 years or even later.
Mutations in the Uromodulin (UMOD) gene were published
in patients with familial juvenile hyperuricemic nephropathy
(FJHN) and MCKD2. Clinical data and blood samples of 16
affected individuals from 11 different kindreds were collected.
Mutational analysis of the UMOD gene was performed by exon
polymerase chain reaction (PCR) and direct sequencing. We
found the heterozygous C744G (Cys248Trp) mutation, which
was originally published by our group, in an additional four
kindreds from Europe and Turkey. Age of onset ranged from
3 years to 39 years. The phenotype showed a variety of
symptoms such as urinary concentration defect, vesicoureteral
reflux, urinary tract infections, hyperuricemia, hypertension,
proteinuria, and renal hypoplasia. Haplotype analysis
showed cosegragation with the phenotype in all eight affected
individuals indicating that the C744G mutation may be due to a
founder effect. Moreover, we describe a novel T229G (Cys77Gly)
mutation in two affecteds of one kindred. Three of the affected
individuals were younger than 10 years at the onset of
MCKD2/FJHN. Symptoms include recurrent urinary tract
infections compatible with the published phenotype of the Umod
knockout mouse model. This emphasizes that MCKD2 is not just
a disease of the young adult but is also relevant for children.
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Medullary cystic kidney disease (MCKD) is a progressive
tubulo-interstitial nephropathy with autosomal dominant
inheritance, which leads to end-stage renal disease (ESRD) in
adulthood.1 Medullary cystic kidney disease type 2 (MCKD2)
(OMIM 603860) includes clinical features of reduced urinary
concentration, salt wasting, and end-stage renal failure. In
contrast to MCKD1, in MCKD2 a more severe phenotype
concerning hyperuricemia and gout has been described.
Moreover, in MCKD2, an earlier median age of onset has
been reported (median age of onset in MCKD2 is 32 years of
age compared to 62 years in MCKD1).2 Otherwise, these two
diseases are clinically undistinguishable. In MCKD small
corticomedullary cysts are common, but not always
detected. Kidney size is normal or only slightly reduced.
MCKD shows a renal histologic triad of (1) tubular basement
disintegration, (2) tubular atrophy with cyst development at
the corticomedullary border, and, (3) interstitial cell infiltra-
tion associated with fibrosis.3 Neither imaging results,
nor pathological findings are pathognomonic for MCKD2.
The condition shares clinical and morphological similarities
to recessive juvenile nephronophthisis (NPH).4 In contrast
to juvenile onset in NPH, end-stage renal failure in
MCKD occurs in adulthood. Moreover, NPH is inherited
in an autosomal recessive pattern, whereas MCKD is auto-
somal dominant.
MCKD2 was localized on chromosome 16p12 in an Italian
family2 and the responsible gene has been identified.5
Missense mutations in the uromodulin (UMOD) gene have
been detected in four MCKD kindreds first by Hart et al.5 It
was then confirmed in 34 additional MCKD kindreds by
others including our group.6–8 Surprisingly, homozygous
UMOD mutations were described too, causing a more
severe phenotype in the affected individuals.9 Besides
MCKD2, UMOD mutations have also been reported
in familial juvenile hyperuremic nephropathy (FJHN) and
in autosomal dominant glomerulocystic kidney disease.10
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UMOD mutations alter the encoded Tamm–Horsfall protein
(THP), the most abundant urine protein in humans. THP is
expressed primarily at the luminal side of renal epithelial cells
of the thick ascending loop of Henle and of early distal
convoluted tubules. The vast majority of mutations were
found in exon 4, which encodes for a calcium-binding EGF
(epidermal growth factor) domain and change cysteine
amino acids, which form disulfide bonds. Decreased urinary
UMOD excretion and retention of the misfolded UMOD
protein in the endoplasmatic reticulum, resulting in an
increased rate of apoptosis, was described.8
UMOD is a transmembrane protein, which can be secreted
into the urine by cleavage of the GPI anchor.11 Functional
roles of THP have been described as a protective factor in
urinary tract infections, in binding to complement factors, in
myeloma kidney, and in nephrolithiasis.12–15
Recently, Hodanova et al.16 published an additional
chromosomal locus for uromodulin-associated kidney
disease on chromosome 1q41. Further evidence of
genetic heterogeneity in FJHN/MCKD2 was shown by
Vylet0al et al.,17 who identified only six UMOD mutations
in 19 kindreds.
We here report the first mutation in UMOD, which is
found in five different kindreds. This finding may be owing
to a founder effect. We observe that the same mutation causes
FJHN in some patients and MCKD2 in other patients. In
addition, we present a novel UMOD mutation in exon 4.
RESULTS
Clinical data
The five families presenting with UMOD mutations included
eight living individuals affected with MCKD/FJHN. Four of
six also suffered from hyperuricemia (Table 1). The patients
presented with hyperuricemia between 3 and 39 years of age
(Table 1). ESRD developed between 6 and 52 years. Imaging
by ultrasound revealed in all families pathologic results
Table 1 | Synopsis of the clinical data, imaging results, renal histology of UMOD patients with a C744G (Cys248Trp) mutation
Family
number Sex
Age at
presentation
Age at
ESRD
PCra
(mg/dl)
GFRa
(ml/min/1.73m2)
PUAa
(mg/dl) Clinical symptoms Imaging Histology
F739
I-1 M 39 45 8.4m NA 5.3 CRI US (small kidneys) NA
II-1 M 18 NA 1.9m 63k 6.6m CRI, hyperuricemia US (small kidneys,
reduced parenchyma,
one cyst)
Interstitial fibrosis,
atrophic tubuli,
sclerosed glomeruli,
thickened basement
membrane
II-2 F 17 NA NA NA NA CRI, hyperuricemia NA NA
K7
I-1 F 9 18 1.4m 70k 5.4 Enuresis nocturna,
VUR, multiple UTI,
proteinuria, CRI, mild
hyperuricemia, NTX,
NTX rejection
US (small kidneys,
echogenic, diminished
cortico-medullary
differentiation, multiple
cysts in right kidney)
NA
K8
I-2 F 42 NA 0.6 NA 4.1 Hypertension
II-2 M 9 NA 1.7m 63k 6.4m CRI, hyperuricemia,
renal hypoplasia of
right kidney,
proteinuria
US (small right kidney,
both kidneys with
echogenic parenchyma,
no cysts)
NA
K10
I-1 M 3 6 0.9m 62k 7.5m CRI, hyperuricemia,
urinary concentration
defect, hypertension,
mild proteinuria
US (small kidneys,
diminished
corticomedullary
differentiation, no cysts)
Focal dysplastic renal
parenchyma, atrophic
tubuli, interstitial fibrosis
K11
I-1 F 46 52 1.5m 58k 5.4 CRI, hypertension,
mild proteinuria,
mild hyperuricemia,
dialysis
US (normal size of
kidney, 4–5 cortical
cysts in each kidney,
up to 3 cm in
diameter)
Tubulo-interstitial
sclerosis and fibrosis
with interstitial
lymphocytic cell
infiltration, atrophic
tubuli, thickened
basement membrane,
staining of THP under
Bowman capsule
CRI, chronic renal insufficiency; GFR, glomerular filtration rate; NTX, renal transplant; PCr, plasma creatinine; PUA, plasma uric acid; NA, not available; US, ultrasound; UTI,
urinary tract infection; VUR, vesico-ureteral reflux; THP, Tamm–Horsfall protein; age at presentation and age at end-stage renal disease (ESRD) are given in years.
aArrows denote increase vs decrease in relation to age-dependent normal values.
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Table 2 | Synopsis of the clinicial data, imaging results, renal histology of UMOD patients with a T229G (Cys77Gly) mutation.
Family
number Sex
Age at
presentation
Age at
ESRD
PCra
(mg/dl)
GFR a
(ml/min/1.73m2)
PUAa
(mg/dl) Clinical symptoms Imaging Histology
A214
I-1 M 39 45 NA NA NA CRI, hyperuricemia,
hemodialysis
US (small kidneys) ‘Chronic
glomerulonephritis’
II-1 M 13 NA 1.2 89 8.2 CRI, hyperuricemia,
urinary concentration
defect, duplicated
urethral opening
US (small kidneys,
reduced parenchyma,
one cyst)
Interstitial fibrosis,
microcysts, thickened
Bowman capsule,
tubular atrophy,
thickened basement
membrane
CRI, chronic renal insufficiency; GFR, glomerular filtration rate; PCr, plasma creatinine; PUA, plasma uric acid; NA, not available; US, ultrasound; age at presentation and age at
end-stage renal disease (ESRD) is given in years.
aArrows denote increase vs decrease in relation to age-dependent normal values.
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Figure 1 | Pedigrees and results of the haplotype analysis in all kindreds with the C744G (Cys248Trp) mutation. Circles denote female
patients, squares denote male patients. Filled symbols denote affected individuals, crosshatches denote deceased individuals. Roman numerals
denote generations. Arrows denote individuals in whom DNA was available for haplotype analysis. Inferred haplotypes are shown in
parenthesis. Differently shaded bars symbolize haplotypes. Paternal haplotypes are drawn to the left, maternal haplotypes to the right. Marker
positions are indicated with left individuals. In two kindreds (K10 and K11), no DNA samples of the parents were available. Therefore, in these
two individuals, the alleles could not clearly assigned to one haplotype. Under the hypothesis of a shared haplotype, the haplotype colored in
black showed cosegregation with the phenotype in all eight living affected individuals of the five different kindreds. Only the microsatellite
D16S3054 shows different alleles in K8 and F739 (240 bp) compared to K7, K10, and K11 (244 bp). This difference can be attributed to a
mutation in the microsatellite repeat.
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including small kidneys, decreased parenchyma, or cysts.
Renal histology in four cases was compatible with MCKD
(Tables 1 and 2). F739 has been presented in Wolf et al.6 The
pedigrees of all kindreds, except A214, are shown in Figure 1.
K7. This female patient is now 24 years old. She is of
Italian descent. A paternal sister, the twin brother of her
father and her paternal grandmother suffered from ESRD,
starting in their early twenties. Her aunt and her uncle
received a kidney transplant. Her father suffered from
hypertension, but was otherwise healthy. At the age of nine
years, she developed enuresis nocturna and the diagnosis of
vesico-ureteral reflux was made. The initial serum creatinine
was 1.4 mg/dl. Surgical correction by ureteroplasty was
performed. After surgery, she continued to suffer from
recurrent urinary tract infections. Renal ultrasound revealed
reduced bilateral kidney size. At the age of 13 years, her renal
function deteriorated (serum creatinine 1.8 mg/dl). She
presented with a non-selective gross proteinuria (1.3 g/24 h)
and became hypertensive (140/70 mm Hg). Unfortunately,
there are only scant data about her plasma uric acid available.
The plasma uric acid at the age of 18 years was 5.4 mg/dl while
on intermittent hemodialysis. At this age, she had developed
symptoms of ESRD and was started on hemodialysis. At the
age of 21 years, she received a living-related donor kidney from
her mother. Five months later, she experienced an acute
transplant rejection and hemodialysis was reinitiated. At the
age of 23 years, she became pregnant under dialysis and
delivered twins in the 30th week of gestation age.
K8. This is a boy of 13 years of age and of Turkish
descent. There is no family history of renal disease. At the age
of nine years, the boy underwent emergency surgery because
of a perforated appendix. Blood analysis revealed an
increased creatinine value of 1.7 mg/dl. During follow-up,
right renal hypoplasia was diagnosed by i.v. scintigraphy with
relative renal functions of 26% on the right-hand side and
74% on the left-hand side. In the ultrasound, no renal cysts
but a small, echogenic, right kidney was noted. At that time,
his creatinine clearance was 63 ml/min/1.73m2. Hyperurice-
mia was noted at the age of 10 years (6.4 mg/dl). Selective
glomerular proteinuria (1.26 g/24 h) and reduced urinary
excretion of uric acid (Fe in Urate¼ 3.85%) were detected at
the age of 12 years. Uric acid increased to 8.8 mg/dl. The
proteinuria is currently improving under treatment with
ramipiril (0.35 g/24 h). Urinary excretion of UMOD was
markedly reduced (Figure 2). By mutational analysis, his
mother was identified as the carrier of the mutation. Except
for hypertension, she was otherwise healthy (Table 1). She
refused further clinical diagnostics.
K10. This is a boy of 14 years who is of German descent.
His family is from Thuringia. As an infant, he showed
symptoms of renal tubular acidosis and reduced urinary
concentration capacity with a maximum urinary osmolality
of 460 mosmol/kg H2O. At the age of 3 years, he presented
with an increased serum creatinine of 0.9 mg/dl and
hyperuricemia (7.5 mg/dl). His creatinine clearance was
already markedly reduced (62 ml/min/1.73m2). Renal biopsy
showed focal dysplastic renal parenchyma, atrophic tubuli,
and interstitial fibrosis. Renal ultrasound revealed small
kidneys, diminished corticomedullary differentiation but no
cysts. At the age of 6 years, he developed persistent
proteinuria and at the age of 10 years he presented with
hypertension. Since 3 years of age, he has been treated with
allopurinol, which seems to have only a limited effect on
preservation of his renal function. The social situation of the
family is very tense and the parents refused further
collaboration.
K11. This is a 53-year-old female patient from Switzer-
land. There was no family history of renal disease. She first
presented with hypertension and mild proteinuria (460 mg/
day) at the age of 46 years. At that time, her creatinine was
1.5 mg/dl and her uric acid was normal at 5.4 mg/dl. Renal
ultrasound showed four to five cortical cysts in each kidney
with a diameter of 1–3 cm. Kidney size was normal.
Renal biopsy was performed at the age of 49 years when
renal function was further deteriorating with a creatinine
value of 2.4 mg/dl. Renal biopsy revealed tubulo-interstitial
sclerosis and fibrosis with interstitial lymphocytic cell
infiltration, atrophic tubuli, thickened basement membrane,
and staining of Tamm–Horsfall protein under the Bowman
capsule. Urinary excretion of UMOD was markedly
reduced (Figure 1). At the age of 52 years, peritoneal dialysis
was initiated.
A214. This is a 21 years old male from the United States
of America (Table 2). Family history is positive, as his father
suffers from ESRD and receives hemodialysis. Two renal
biopsies in the father were described as showing chronic
glomerulonephritis (Table 2). At the age of 13 years, the
patient’s blood chemistry showed an elevated creatinine value
of 1.2 mg/dl and hyperuricemia (8.2 mg/dl). Renal ultrasound
showed small kidneys, reduced parenchyma and one cyst. He
was normotensive but showed a urinary concentration defect
20
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kDa 1 2 43 1 2 43
Coomassie UMOD
kDa
97
66
45
30
20
Figure 2 | Urinary UMOD excretion in relation to total urinary
protein excretion. The first four lanes on the left-hand side show
Coomassie urinary protein staining for individual K8 (lane 1), healthy
controls (lanes 2 and 3), and individual K11 (lane 4), indicating
additional bands of urinary protein in K11. The band with a size of
66 kDa corresponds to albumin. On the right-hand side, the
corresponding Western blot for urinary UMOD staining is shown.
In lanes 2 and 3, strong staining for UMOD in the healthy controls
was found. In lane 1 (K8) and lane 4 (K11), UMOD staining revealed
almost no band for K8 and only a weak band for K11.
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with a specific gravity of 1.008. His glomerular filtration rate
was 89 ml/min/1.73m2. In the following month, his serum
uric acid increased to 9.8 mg/dl, his creatinine rose to 1.4 mg/
dl, and the glomerular filtration rate declined to 76 ml/min/
1.73m2. Renal biopsy at the age of 18 years showed interstitial
fibrosis, microcysts, thickened Bowman capsule, tubular
atrophy, and thickened basement membrane. His serum
creatinine rose to 2.1 mg/dl.
Mutation analysis
We performed mutational analysis in the five affected
individuals described above by exon polymerase chain
reaction (PCR) and direct sequencing of all UMOD exons.
In families K7, K8, K10, and K11, the affected individuals
were analyzed and a C744G mutation was detected, causing
the amino-acid exchange Cys248Trp (Figure 3a). This
mutation was previously found in F739.6 In this publication,
nucleotide numbers were referred to the published mRNA
resulting in the annotation C849G (Cys248Trp). Now we
have changed the annotation starting with nucleotide
number one at the first amino acid coding nucleotide triplet
resulting in the annotation C744G (Cys248Trp).
In family A214, a novel nucleotide exchange T229G
was found, resulting in the amino-acid exchange Cys77Gly
(Figure 3b). The mutation was identified in the affected
father and son.
The previously published C744G mutation and the newly
discovered T229G mutation are both located in exon 4. None
of the mutations were found in 100 healthy Caucasian
controls. Therefore, our detected mutations are unlikely to be
common polymorphisms and most likely disease causing.
Haplotype analysis
Haplotype analysis with seven polymorphic micro-
satellites was performed in all individuals with the C744G
(Cys248Trp) mutation and their relatives as far as available.
In two kindreds (K10 and K11), no DNA samples of the
parents were available. Therefore, in these two individuals,
the alleles could not clearly assigned to one haplotype. Under
the hypothesis of a shared haplotype, the haplotype colored
in black (Figure 1) showed cosegregation with the phenotype
in all eight living affected individuals of the five different
kindreds. Only the microsatellite D16S3054 showed different
alleles in K8 and F739 (240 bp) compared to K7, K10, and
K11 (244 bp). This difference can be attributed to an
ancestral mutation in the microsatellite repeat. Therefore,
we conclude that the C744G mutational hotspot in the five
kindreds may be due to a founder effect.
DISCUSSION
Evaluation of genotype–phenotype correlations in MCKD2
has long been impossible due to the limited number of
patients and the individual character of each mutation for a
kindred. We identified another four kindreds with the same
C744G mutation, which we have published in the German
kindred F739.6 We here present in eight individuals from five
kindreds carrying the same C744G mutation the broad
variation of clinical courses. The five kindreds, including
F739, are from all over Europe and Turkey. Genotype–
phenotype correlation was performed not including the
individuals of kindred A214, because of the different mutation.
Renal cysts were found by renal ultrasound in three of
seven affected individuals, supporting the diagnosis of
MCKD2. A family history compatible with autosomal
dominant inheritance was only found in three kindreds
(K7, K8, and F739). The mother of K8 was only hypertensive.
In two other affected individuals, no family history of renal
disease or hyperuricemia was found. In four affected
individuals, ESRD was diagnosed. The age of onset of ESRD
varied between 6 and 52 years of age. None of the patients
presented with gout. Hyperuricemia was found in all
patients. Interestingly, uric acid was only slightly elevated
in K7, K8, and K11. Including the previously described
kindred F739,6 three of the eight affected individuals show
symptoms by the age of 10 years (one with MCKD2 and two
with FJHN). Only two of eight patients entered renal
insufficiency in the fifth decade of life, emphasizing that
the UMOD-associated diseases should also be taken into
consideration in the field of pediatric nephrology. Haplotype
analysis was performed in all available individuals. Under the
hypothesis of haplotype sharing, cosegregation of the
haplotype colored in black with the phenotype in all eight
living affected individuals was shown (Figure 1). Only the
microsatellite D16S3054 showed different alleles in K8 and
F739 (240 bp) compared to K7, K10, and K11 (244 bp). The
different alleles for D16S3054 can be attributed to an
ancestral mutation in the repeat of the microsatellite marker.
We conclude that the high frequency of the C744G mutation
in the five kindreds may be due to a founder effect. However,
the patients with the C744G mutation come from four
different countries from central Europe and Turkey. Taking
this wide distribution into consideration, we assume that this
mutation may have a much higher frequency and may be
responsible for a larger portion of FJHN/MCKD patients.
Mutations in UMOD have been found to result in
MCKD2, FJHN, and glomerulocystic kidney disease, indicat-
ing a broad variety of clinical symptoms (Table 3).8
FJHN presents with hyperuricemia between childhood
and early adult life (age of onset: 3–17 years) sometimes
causing gout.18 A typical characteristic of FJHN is a
reduced urinary fractional excretion of urate (FEUrat).
Different hypotheses concerning reduced FEUrat are dis-
cussed.19 Reference values for FEUrat differ for male patients
(8.173.2%), female patients (12.872.9%), and children
(12–30%).18,20 The other characteristics of FJHN and
MCKD2 are shown in Table 3. According to these criteria,
we tried to assign the correct diagnosis to the five kindreds.
We diagnosed FJHN in K8 and K10 and MCKD2 in K7 and
K11. F739 would have been compatible with either MCKD2
or FJHN. All affected individuals presented with the same
C744G mutation. Therefore, we are able to confirm the
hypothesis of Dahan et al.,21 by molecular genetics, who
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suspected on the basis of linkage analysis that FJHN and
MCKD2 are facets of the same disease.
K7 was diagnosed with MCKD2 due to renal cysts and
enuresis nocturna, indicating polyuria. Unfortunately there
are scant data about her uric acid levels. Under hemodialysis,
she had serum uric acid levels of 5.4 mg/dl, indicating that
she may not have suffered from severe hyperuricemia.
However, with an age of onset of 9 years, she would have
been very young for the development of MCKD2. Only one
report about MCKD2 in childhood has been published yet.
Bleyer et al.22 described a kindred with MCKD2, in which the
youngest affected patient with an UMOD mutation was just 7
years. Although the author calls the described disease
MCKD2, the clinical characteristics would fit better to FJHN,
as the affected patient showed severe hyperuricemia, a young
age of onset and no renal cysts were described. Hart et al.5
also described a kindred with MCKD2, in which the vast
majority but not all affected individuals have hyperuricemia.
In addition, they showed renal cysts justifying the diagnosis
of MCKD2. This underlines the heterogeneity of the
phenotype.
Interestingly, patient K7 became symptomatic with
recurrent urinary tract infections. An Umod knockout mouse
model with an increased rate of urinary tract infections was
described.23 Nevertheless, this patient also suffered from
vesico-ureteral reflux. So it is difficult to decide whether
infections were caused by vesico-ureteral reflux or the
decreased UMOD secretion. Recurrent urinary tract infec-
tions even after surgery may hint to a potential responsibility
of UMOD for the infections.
Unfortunately, there seems to be incomplete penetrance in
K7. Obviously, the father of K7 was not severely affected,
presenting only with hypertension, but his twin brother and
his sister received a kidney transplant. Incomplete penetrance
was also reported by Bleyer et al., with a mother only
suffering from hyeruricemia without renal impairment but
an affected child with impaired renal function.22 Incomplete
or age-related penetrance should be taken into consideration
when a pedigree is drafted. Incomplete penetrance and the
broad variety of phenotyps may hint at the ‘two hit’ hypothesis
in MCKD2 as it was already shown for ADPKD.24–25 In
addition, ‘transheterozyote’ mutations in MCKD1 and
MCKD2 in analogy to ADPKD, showing heterozygous
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AGC  CGC AAG GCC  TGC  GCG  CAC  TGG  AGC  GGC
 
MUT: 
 AGC  CGC AAG  GCC TGC  GCG CAC  TGG  AGC GGC 
 G
 Cys/Trp
Cys
WT 
CCT  GGA GCT CAC AAC TGC TCC GCC AAC AGC
  Pro
MUT: 
A214 
CCT GGA  GCT CAC AAC TGC TCC  GCC AAC  AGC
G
Pro Gly
Gly
Ala
Ala
His
His
Asn
Asn
Cys/Gly
Cys
Ser
Ser
Ser
Ser
Arg
Arg
Lys
Lys
Ala
Ala
Ala
Ala
His
His
Trp
Trp
Ser
Ser
Gly
Gly
Ala
Ala
Asn
Asn
Ser
Ser
F739 
K7 
K8 
K10 
K11 
a
b
Figure 3 | Mutations in the UMOD gene. The upper sequence shows
the wild-type (WT) sequence and the lower sequence reveals the
mutation (MUT) in each family. The resulting amino acids are indicated
below nucleotide sequences. Both mutations are located in exon 4. The
altered nucleotide and amino acids are shown in red. (a) In affected
individuals of families F739, K7, K8, K10, and K11, a heterozygous
C744G substitution was detected resulting in a Cys248Trp amino-acid
exchange. (b) Affected individuals in family A214 showed a
heterozygous T229G substitution, causing a Cys77Gly change.
Table 3 | Comparison of the characteristics of familial hyperuricemic juvenile nephropathy (FJHN) and medullary cystic kidney
disease type 2 (MCKD2)
FJHN MCKD2
Age at presentation (years) Childhood, adolescence, early adult life Early to later adult life (B32 years)
Age at ESRD (years) 20–40
Symptoms Hyperuricemia, sometimes gout, renal hypoexcretion of urate
(FEurato12% in children), hypertension inconsistently, absent or
minimal proteinuria
Polyuria, salt loss, hyperuricemia, sometimes gout,
No data about FEurat in MCKD2, hypertension, no
data about proteinuria in MCKD2
Ultrasound Echogenic kidneys Small, echogenic kidneys, often with small
medullary cysts, but not necessary for diagnosis
Histopathology Tubular atrophy, fibrosis, interstitial cell infiltration, segmentally
sclerosed glomeruli, thickening of the basement membrane
Like in FJHN plus microcysts and tubular dilation
FEurat, fractional excretion of urate.
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mutations in PKD1 and PKD2, could also result in a more
diverse spectrum of symptoms.24–25 The THP knockout mouse
showed that the mere absence of THP is not sufficient to cause
histological changes associated with MCKD2/FJHN.26
Patient K10 was diagnosed with FJHN but also showed
symptoms of a urinary concentration defect, which is
untypical for FJHN.20 Moreover, this patient has a very early
age of onset with severe clinical symptoms. The youngest
patient with FJHN described was 4 years of age.18 Interest-
ingly, treatment with allopurinol did not preserve renal
function despite its suggestion as an effective treatment.27
Although proteinuria is not a main criterion for the
diagnosis of FJHN or MCKD2, four of the eight patients
showed proteinuria (two with FJHN and two with MCKD2).
Proteinuria ranged from 0.46 g/24 h to 1.3 g/24 h. One patient
was treated with an angiotensin-converting enzyme, reducing
proteinuria significantly.
Taking the described characteristics of FJHN and MCKD2
into account and trying to apply these to the patients with
the C744G mutation, it becomes obvious that no clear-
cut differentiation between FJHN and MCKD2 is possible
(e.g. given the atypical early onset of MCKD2 in K7, renal
hypoplasia in K8, renal concentration defect in K10 with
FJHN). More discrepancies have been published by Hart et al.5
and Bleyer et al.22 Recently, it was published that the THP
knockout mouse does not develop cysts.28 Possibly, the cysts
may develop in some UMOD patients due to secondary effects.
As the molecular pathogenesis is the same for FJHN and
MCKD2, it seems questionable, whether a further differentia-
tion between FJHN and MCKD2 is meaningful. Bleyer et al.22
has already suggested the term uromodulin-associated kidney
disease, which could be subdivided into early-onset and late-
onset uromodulin-associated kidney disease. However, the
molecular basis for the broad clinical variety remains elusive.
The Cys248Trp mutation is located in a recently described
new D8C domain.29 The cysteine at position 248 is also
conserved in D8C domains of other genes as LZP variants,
LZP and GP-2. The D8C domain consists of eight conserved
cysteine residues that are probably involved in disulfide bond
formation. Cys248 is supposed to form a disulfide bridge
with Cys 256.29
The T229G mutation alters the amino-acid Cys77Gly in
A214. The same amino acid has already been published to be
changed in FJHN – but by a different mutation (G230A,
Cys77Tyr).30 Both mutations (Cys77Gly and Cys248Trp)
involve cysteine residues, which are highly conserved in the
UMOD protein throughout evolution. The high cysteine
content of THP (48 cysteine residues forming 24 disulfide
bonds) and correct formation of the disulfide bonds were
suspected to be the rate-limiting step for the export of the
premature THP out the endoplasmatic reticulum, which
regulates the efficiency of THP maturation.31 This results
in decreased urinary UMOD excretion and retention of
the misfolded UMOD protein in the endoplasmatic reten-
tion, causing an increased rate of apoptosis. Interestingly, this
effect was reversed in cell culture by treatment with
colchicine or a chaperone (sodium 4-phenylbutyrate).32
Colchicine is a common treatment for gout. Further studies
will have to show whether this will be a future therapeutical
option for patients with MCKD/FJHN too.
MATERIALS AND METHODS
Patients
We ascertained 16 MCKD individuals from 11 different families.
Seven families are from Germany, one comes from Switzerland, one
from Italy, one from the USA, and one from Turkey. Age at
diagnosis, age at onset of ESRD, hyperuricemia, imaging data, and
biopsy results were reviewed if available. Diagnostic criteria were
normal or small-sized kidneys with occasional small corticomedul-
lary cysts and renal insufficiency. At least one of the optional criteria
as hypertension, a family history of renal disease, reduced fractional
urinary excretion of uric acid, or hyperuricemia was demanded.
Hyperuricemia was defined as serum uric acid concentration 41 SD
higher than the normal values for age and gender.33 The study was
approved by the ethics committees of the Albert-Ludwigs-University
Freiburg and the University Hospital Cologne. All participating
family members provided informed consent.
Haplotype analysis of the UMOD gene
To analyze linkage to the MCKD2 locus, we performed haplo-
type analysis with seven polymorphic microsatellite markers:
cen – D16S3076 – D16S3045 – D16S3054 – D16S3099 – D16S749
– D16S3036 – D16S3041 – tel. Fluorescently labeled PCR products
were detected by a Genetic Analyzer 3100TM (Applied Biosystems,
Foster City, CA, USA) and were analyzed by the GENOTYPERTM
software.
Mutational analysis of the UMOD gene
Mutational analysis was performed by exon PCR of the Uromodulin
gene. Primer sequences were used as described by Wolf et al.6 PCR
products were purified using the Marligen Rapid PCR Purification
System. Purified PCR products were sequenced, using a Genetic
Analyzer 3700 (Applied Biosystems) and resulting sequences were
evaluated with the SequencherTM Software.
Urinary excretion of UMOD
Western blot analysis for UMOD staining was performed according
to Rampoldi et al.8
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